

RESEARCH ARTICLE

Mitochondrial Ultrastructural Alterations and Declined M₂ Receptor Density Were Involved in Cardiac Dysfunction in Rats after Long Term Treatment with Autoantibodies against M₂ Muscarinic Receptor

Suli Zhang^{1,2}, Zhongmei He³, Jin Wang³, Li Wang⁴, Ye Wu^{1,2}, Jie Wang⁵, Tingting Lv¹, Huirong Liu^{1,3,6*}

1 Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Capital Medical University, Beijing, 100069, P. R. China, **2** The Key Laboratory of Remodeling-related Cardiovascular Diseases, Capital Medical University, Ministry of Education, Beijing, 100069, P. R. China, **3** Department of Physiology, School of Basic Medical Sciences, Shanxi Medical University, Taiyuan, Shanxi, 030001, P. R. China, **4** Department of Pathology, School of Basic Medical Sciences, Shanxi Medical University, Taiyuan, Shanxi, 030001, P. R. China, **5** Department of Neurology, First Hospital of Shanxi Medical University, Taiyuan, Shanxi, 030001, P. R. China, **6** Beijing Key Laboratory of Metabolic Disorders Related Cardiovascular Diseases, Capital Medical University, Beijing, 100069, P. R. China

☞ These authors contributed equally to this work.

* liuhr2000@126.com



CrossMark
click for updates

OPEN ACCESS

Citation: Zhang S, He Z, Wang J, Wang L, Wu Y, Wang J, et al. (2015) Mitochondrial Ultrastructural Alterations and Declined M₂ Receptor Density Were Involved in Cardiac Dysfunction in Rats after Long Term Treatment with Autoantibodies against M₂ Muscarinic Receptor. PLoS ONE 10(6): e0129563. doi:10.1371/journal.pone.0129563

Academic Editor: Jing Ai, Harbin Medical University, CHINA

Received: October 19, 2014

Accepted: May 11, 2015

Published: June 18, 2015

Copyright: © 2015 Zhang et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: All relevant data are within the paper and its Supporting Information files.

Funding: This study was supported by grants from the 973 Program Earlier Research Project (2014CB560704) to Huirong Liu (<http://program.most.gov.cn/>); the National Natural Science Foundation Youth Project (81300694) to Suli Zhang (<http://www.nsf.gov.cn/>); the 2013 Specialized Research Fund for Doctoral Program of Higher Education (20131107120021) to Suli Zhang (<http://www.moe.gov.cn/>); and grants from the Scientific Research

Abstract

Background

Previous studies showed that autoantibodies (M₂-AA) against the second extracellular loop of M₂ muscarinic receptor (M₂AChR-el2) from dilated cardiomyopathy (DCM) serum could induce DCM-like morphological changes in mice hearts. However, the effects of M₂-AA on the cardiac function during the process of DCM and the potential mechanisms are not fully known. The present study was designed to dynamically observe the cardiac function, mitochondrial changes, and M₂ receptor binding characteristics in rats long-term stimulated with M₂-AA *in vivo*.

Methods

M₂-AA-positive model was established by actively immunizing healthy male Wistar rats with synthetic M₂AChR-el2 peptide for 18 months. Meanwhile, vehicle group rats were administered with physiological saline. The change of mitochondrial membrane potential ($\Delta\Psi_m$) was detected by radionuclide imaging. The ultrastructure of mitochondria was observed under electron microscopy. The M₂ receptor binding characteristics were determined by radioactive ligand binding assay.

Base Construction-Scientific and Technological Innovation Platform-Metabolic Disorders Related Cardiovascular Diseases Research Platform Construction (municipal level) (PXM2014_014226_000038; <http://www.bjedu.gov.cn/publish/portal27/>). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

Results

After immunization for 12 months, compared with vehicle group, M₂AChR-el2-immunized rats showed decreased myocardial contractility and cardiac diastolic function evidenced by declined maximal rate of rise of ventricular pressure and increased left ventricular end-diastolic pressure, respectively. Additionally, mitochondrial swelling and vacuolation were observed. At 18 months, M₂AChR-el2-immunized rats manifested significant decreased cardiac systolic and diastolic function and pathological changes such as enlargement of right ventricular cavity and wall thinning; and the mitochondrial damage was aggravated. Furthermore, the M₂ receptor maximum binding capacity (B_{max}) of the M₂AChR-el2-immunized rats significantly decreased, while the M₂ receptor dissociation constant (K_d) was increased.

Conclusions

Our study suggested that long-term stimulation with M₂-AA led to the ventricular dilatation and gradual deterioration of cardiac dysfunction. Mitochondrial damage and the down-regulation of M₂ receptor density and affinity may be involved in the process.

Introduction

Idiopathic dilated cardiomyopathy (DCM), a refractory and primary myocardial disease, is a major cause of death in patients with heart failure. However, the pathogenesis of DCM is not fully understood. Autoimmunity, viral infection, and genetic predisposition have long been considered as major causes for idiopathic DCM, among which autoantibodies have become one of the cornerstones in mediating the pathophysiology in these patients [1].

It has long been known that there are high titers of autoantibodies against the second extracellular loop of the M₂ muscarinic receptor (M₂-AA) in sera of patients with DCM [2]. Our previous study showed that both M₂-AA positive rate and titer in the sera of 53 DCM patients were higher than those in 408 healthy subjects [3]. A previous study demonstrated that M₂-AA could recognize the second extracellular loop of the M₂ muscarinic receptor (M₂AChR-el2) and stimulate the muscarinic receptor on rats' heart membrane [4]. Recent studies also indicated that M₂-AA was responsible for DCM-like morphological changes in mice that were immunized with M₂ receptor for 8 weeks [5]. However, whether long term exposure to M₂-AA can worsen cardiac function during progression of DCM remains largely unknown.

Metabolic disorder is one of the key mechanisms of cardiac dysfunction in DCM, which is mainly caused by mitochondrial injury. Existing evidence suggests that mitochondrial injury in a rat model of DCM is responsible for cardiac dysfunction [6]. A clinical study has also shown that mitochondrial dysfunction could aggravate the pathogenicity of DCM [7]. These reports suggest that mitochondrial injury plays a detrimental role in the pathogenesis of DCM. However, whether long-term stimulation by M₂-AA could contribute to mitochondrial injury in myocardium of DCM is still undetermined.

M₂ receptor is an essential molecule in cardiac function regulation (i.e. negative inotropy and chronotropy), which displays contrarian functions to those of β₁-adrenoceptors. M₂ receptor activation also plays important roles in regulation of mitochondrial function [8]. Studies have shown that like other G protein-coupled receptors, the expression and affinity of M₂ receptor can be up- or down-regulated by a multitude of factors, such as agonist, antagonist [9],

and stress [10]. Additionally, abnormal receptor function may cause weakened cardio-protective effects of M₂ receptor. A previous study reported that M₂-AA isolated from patients with DCM can directly activate M₂ receptor and exhibit agonist-like effects [11]. However, whether changes of binding characteristics of M₂ receptor are responsible for the M₂-AA-induced cardiac dysfunction are still unknown.

In the present study, healthy rats were immunized with the synthetic peptide of M₂AChR-el2 to clarify the pathological roles of M₂-AA in DCM. We aimed to determine the progress of cardiac dysfunction, changes of mitochondrial membrane potential and ultrastructure, and M₂ receptor binding characteristics in the M₂-AA positive rat model.

Materials and Methods

Peptide Synthesis

The peptide-corresponding to the sequence of the second extracellular loop of the human muscarinic receptor-2 (residues 168–193, V-R-T-V-E-D-G-E-C-Y-I-Q-F-F-S-N-A-A-V-T-F-G-T-A-I-A, 95% purity) [4] was synthesized by Shanghai Biochemical Institute of Chinese Medical Science Academy using an automated peptide synthesizer. The peptides were purified by reverse phase HPLC on a C-18 column (Vydac, Hesperia, CA) and assessed on an automated amino acid analyzer (Beckman Instruments, CA).

Immunization of animals

Ten-week old healthy male Wistar rats, lacking congenital M₂-AA, were divided into two groups. The M₂-AA group (n = 30) was immunized with a mixture of synthetic peptides corresponding to M₂AChR-el2 and immunoadjuvants once a month for 18 months, and the vehicle group (n = 30) was immunized with a mixture of physiological saline and immunoadjuvants. The immunizing antigen was dissolved in 0.1 mol/L Na₂CO₃ solution (pH = 11.0). In the M₂-AA group, rats were immunized based on body weight with 0.4 mg/kg of M₂AChR-el2 peptide, which was emulsified in an equal volume of Complete Freund's adjuvant (CFA) and injected subcutaneously. After a month, a booster injection of a mixture of the same dose of M₂AChR-el2 antigen peptide with equal volume of Incomplete Freund's adjuvant (IFA) was administered subcutaneously. CFA contains paraffin oil, mannide monooleate and killed mycobacterium tuberculosis, which can attract macrophages to the injection site and enhance immune response. On the other hand, IFA contains paraffin oil, mannide monooleate but lacks bacteria, therefore can minimize the side effects of adjuvant, and was thus used for the immunization boosts. The rats of the vehicle group received the mixture of physiological saline and adjuvant according to the procedure as described above. All rats were bled one day before each booster injection and sera collected. At the end of immunization, rats were executed to collect the hearts and sera samples. Carbon dioxide (CO₂) inhalation was used for euthanasia of rats. The study conformed to AVMA Guidelines on Euthanasia and the Guide for the Care and Use of Laboratory Animals protocol published by the Ministry of the People's Republic of China and were approved by Shanxi Medical University Committee on Animal Care. During the study period, the rats were fed with rat chow and water ad libitum.

Streptavidin-enzyme-linked immunosorbent assay (ELISA)

Blood samples were collected from the caudal veins pre-immunization every month. The sera was separated by centrifugation at 3000 g for 15 min, aliquoted and frozen at -20°C until analysis. The titers of M₂-AA were dynamically measured by ELISA as reported previously [3], and the results were expressed as optical density (OD) values. The OD value was measured at 405

nm using an ELISA reader (Spectra Max Plus, Molecular Devices, Sunnyvale, California, USA). We also calculated the positive/negative (P/N) ratio [(the OD of sample—the OD of blank control) / (the OD of negative control—the OD of blank control)] of each sample. Negative control samples were prepared as follows: 100 sera samples from healthy rats with an OD value of less than 2.5 times the background OD were pooled and centrifuged at 1500 rpm for 10 min, and the supernatants were then divided into small aliquots and stored until use. Samples with a P/N value of ≥ 2.1 were considered as M₂-AA-positive, and samples with a P/N value of ≤ 1.5 were considered as M₂-AA-negative [12].

Measurement of cardiac function *in vivo*

The rats were anesthetized with sodium pentobarbital (50 mg/kg, i.p.) and the left ventricle was catheterized with a Statham gauge (PE50) through the right common carotid artery. Then left ventricular function was measured and the data were recorded by the PowerLab data acquisition system (AD Instruments). The following primary and derived variables were continuously recorded on a beat-to-beat basis: left ventricular systolic pressure (LVSP), left ventricular end diastolic pressure (LVEDP), and maximal rate of rise and decline of ventricular pressure ($\pm dp/dt_{\max}$).

Cardiac morphological and histopathological analysis

Histopathologic examination of the hearts was performed after routine fixation and paraffin embedding. The wall thickness, cavity dimension, and cavity area were measured at the mid-sections of each heart by a computerized image analysis system (MIAS-300, Sichuan, China).

Heart tissues were fixed with glutaraldehyde for transmission electron microscopy analysis. Briefly, small pieces of heart tissue were fixed with 2.5% glutaraldehyde in 0.1 mol/L phosphate buffer (pH 7.4) for 2 h at 4°C. After being washed with phosphate buffer, the specimens were post-fixed with 1% osmium tetroxide for 2 h at 4°C. Following dehydration with a graded series of acetone, the specimens were infiltrated with epoxies 618 ultra-thin sections (50 nm thicknesses) and cut using a LKB ultra-microtome IV after polymerization at 60°C, stained with uranyl acetate and lead citrate, and finally observed using a 100-CX transmission electron microscope (Japan).

Myocardial radionuclide imaging

Myocardial radionuclide imaging was used to detect the mitochondrial membrane potential ($\Delta\Psi_m$) [13]. Myocardial uptake of ^{99m}Tc methoxyisobutylisonitrile (^{99m}Tc-MIBI) was measured as heart and upper mediastinum (H/M) count ratio. The operation was performed as previously described [14]. Briefly, an 18.5-MBq dosage of ^{99m}Tc-MIBI was slowly injected *via* rat tail vein and planar and single photon emission computed tomography views were obtained. Conventional gamma scintillation camera was utilized for image processing (Mobile Radioisotope Camera, Model BHP6602, Hamamatsu, Japan).

Radio-ligand receptor binding assay (RBA)

Rats were sacrificed at 12 and 18 months after the initial immunization. Tissue preparation was performed using methods previously reported by Vandermolen *et al.* [15]. Briefly, left ventricles from each group were collected and rapidly frozen in liquid nitrogen, and then stored at -70°C until sectioning. Ventricular tissue was trimmed to a dimension of 5×5 mm and embedded in OCT media (Miles, USA). The tissue sections were consecutively cut 40 μ m in thickness in a -18°C cryostat microtome (Ryocut 1800) with their serial order being noted. One of five

consecutive sections, which were made into a set, was used to measure tissue protein *via* Bradford method to ensure that consecutive serial sections did not vary in size [16]. [³H]-quinuclidinyl benzylate ([³H]-QNB, 51 Ci/mmol, Amersham International, UK) was used as radioligand for M₂-muscarinic receptor. Saturation-binding isotherms were obtained by incubating sections for 1h with varying concentrations of [³H]-QNB (0.125 nM–8 nM) at 26°C, and experiments performed in duplicate. The reaction was terminated by dipping slides into 0°C Tris buffer for 22 min. The slides were rapidly dried and each set of four consecutive sections was scraped from the slides with a blade into tubes respectively, and individual scintillation vials with 5 ml scintillation fluid (PPO 4 g, Popop 100 g, dissolved in 1000 ml xylol) was added to each vial and stabilized overnight and counted in a liquid scintillation counter (Beckman LS-3801) for muscarinic binding. Non-specific binding was determined in the presence of 10⁻⁴ mol/L atropine and amounted to less than 20% of total binding. Specific binding was obtained by subtracting non-specific binding from total binding. All binding data are given as specific binding. The saturation binding parameters B_{max} and K_d were determined using the Prism 2.01 Programs.

Statistical analysis

All measured values are expressed as mean ± SEM. Data was analyzed by unpaired Student's *t* test or ANOVA where appropriate. The analyses were carried out using SPSS 13.0 software. Statistical significance was set at $P < 0.05$.

Results

M₂-AA-positive rat models were successfully established and resulted in dilated cardiomyopathy-like morphological features

To determine the effect of long-term existence of M₂-AA on cardiac structure and function *in vivo*, a M₂-AA-positive rat model was established by active immunization with synthetic M₂AChR-el2 antigen peptides for 18 months. Serum levels of M₂-AA were detected by ELISA. In the immunization group, three rats (No. 3, 18 and 29) were euthanized after the 2nd month for failing to generate M₂-AA ($P/N \leq 1.5$). One rat (No.15) was euthanized due to inflammation at inoculation site after the 3rd month. In the vehicle group, two rats (No.4, 16) were euthanized because of malocclusion induced-excessive weight loss and inflammation at inoculation site after the 2nd and 3rd month, respectively. One rat (No.30) died unexpectedly at the 4th month. Therefore, there were 26 rats in the M₂AChR-el2-immunized group and 27 rats in the vehicle group. During the immunization period, the M₂-AA were positive ($P/N \geq 2.1$) in the M₂AChR-el2-immunized group and maintained at a high level (Fig 1A), which peaked at the 11th month (OD value, 1.76±0.14 vs. 0.39±0.07, $P < 0.01$) and then declined gradually. The average titer of the antibodies during the 18 months was 1:1168.3±29.6. The M₂-AA remained negative ($P/N \leq 1.5$) in the vehicle group throughout the observation period. The level and variance trends of M₂-AA in the M₂AChR-el2-immunized group were matched with the detected result of clinical patients, which indicates that this autoimmunity animal model was able to imitate clinical pathological progress.

The morphology of the hearts excised from the rats was observed post-immunization. As shown in Fig 1B, hearts from the M₂-AA-positive immunization group showed moderate dilatation in the ventricles, including wall thinning. The dilatation was more apparent in the right ventricle (RV) than the left ventricle (LV), the RV/LV ratios of hearts from the M₂-AA group increased significantly in cavity dimension and cavity area, while the wall thickness decreased significantly (Table 1) compared with the hearts from rats in vehicle group.




Fig 1. Establishment of M₂-AA-positive rat models by actively immunizing with M₂AChR-el2 antigen peptides for 18 months. (A) Time courses of M₂-AA production during the process of active immunization in rats. Data are presented as mean ± SEM of optical density (OD) values measured by ELISA from three independent experiments at dilution of 1/640. The M₂-AA group (n = 26) was immunized with a mixture of M₂AChR-el2 antigen peptides and immunologic adjuvant, the vehicle group (n = 27) was immunized with a mixture of physiological saline and immunologic adjuvant. *P<0.05, **P<0.01 vs. vehicle group at the respective time-point. (B) Observation of the transverse sections of the hearts after 18 months of immunization with M₂AChR-el2 antigen peptides. Hearts from the vehicle group showed normal chamber size and wall thickness, while hearts from the M₂-AA group showed dilatation of the right ventricle with wall thinning. M₂-AA, autoantibodies against M₂ muscarinic receptor; M₂AChR-el2, the second extracellular loop of M₂ muscarinic receptor.

doi:10.1371/journal.pone.0129563.g001

Long-term active immunization with M₂AChR-el2 peptide induced cardiac dysfunction in rats

To observe whether long-term active immunization with the M₂AChR-el2 peptide influenced cardiac function in rats, hemodynamics parameters to evaluate left ventricular systolic and diastolic function were measured at 6, 12, and 18 months post-immunization. As shown in Fig 2, compared with the vehicle group, the left ventricular systolic pressure (LVSP) in the M₂AChR-el2-immunized group had no significant change at the 12th month, but markedly decreased at the 18th month (Fig 2A). The left ventricular end-diastolic pressure (LVEDP) in the M₂ group increased at the 12th month (1.5±1.3 KPa vs. 1.1±0.8 KPa, P<0.05), and further increased at the 18th month (2.9±1.1 KPa vs. 1.2±0.8 KPa, P<0.01) (Fig 2B). The maximal rate of rise of left ventricular pressure (+dP/dt_{max}) decreased at the 12th month (302.4±39.0 KPa/s vs. 369.1±36.2 KPa/s, P<0.05) and decreased significantly at the 18th month (213.0±40.3 KPa/s vs. 330.3±29.6 KPa/s, P<0.01) (Fig 2C). In addition, the maximal rate of decline of left ventricular pressure (-dP/dt_{max}) increased significantly until the 18th month (-163.6±28.4 KPa/s vs. -225.5±12.7

Table 1. RV/LV ratios from anatomic measurements of rat hearts at the end of the experiment.

Group	Wall thickness	Cavity dimension	Cavity area
Vehicle group	0.51±0.17	0.78±0.19	0.30±0.08
M ₂ -AA group	0.42±0.07*	1.06±0.39**	1.51±0.24**

Data are presented as mean ± SEM (n = 5). RV: right ventricle; LV: left ventricle; M₂-AA, autoantibodies against M₂ muscarinic receptor.

*P<0.05.

**P<0.01 vs. control group.

doi:10.1371/journal.pone.0129563.t001




Fig 2. Dynamic monitoring of the left ventricular function changes of rats immunized with M₂AChR-el2 for 18 months. Data are presented as mean ± SEM (n = 6). Panel A: left ventricular systolic pressure (LVSP, kPa); Panel B: left ventricular end diastolic pressure (LVEDP, kPa); Panel C: maximal rate of rise of left ventricular pressure (+dp/dt_{max}, kPa/s); Panel D: maximal rate of decline of left ventricular pressure (-dp/dt_{max}, kPa/s). *P<0.05, **P<0.01 vs. vehicle group at the corresponding time point.

doi:10.1371/journal.pone.0129563.g002

KPa/s, P<0.01) (Fig 2D). These results indicated that the cardiac function underwent no change in the first 6 months after M₂AChR-el2 immunization; however, diastolic function and myocardial contractility of LV worsened at the 12th month, and both the systolic and diastolic function of LV resulted in serious deterioration at the 18th month post-immunization.

Active immunization rats with M₂AChR-el2 peptide caused a decrease in myocardial ΔΨ_m and structural changes of mitochondria

Mitochondrial membrane potential (ΔΨ_m) is an important parameter of mitochondrial function [17]. Given that approximately 90% of myocardial ^{99m}Tc-MIBI is localized within mitochondria and myocardial uptake of ^{99m}Tc-MIBI is dependent on ΔΨ_m, the current study used radionuclide ^{99m}Tc-MIBI myocardial perfusion imaging method to determine the alteration in ΔΨ_m as reported previously [14]. The regions of interest positioned over the heart (H) and upper mediastinum (M) represent the ^{99m}Tc-MIBI uptake in the heart and mediastinum, respectively, and H/M uptake ratio can reflect the myocardial ΔΨ_m changes. As shown in Fig 3A, at the 12th month post initial immunization, ^{99m}Tc-MIBI uptake ratio of heart to mediastinum in M₂-AA group rats decreased compared to vehicle group rats (1.63±0.05 vs. 2.07±0.09, P<0.05), which indicated that long-term exposure of M₂-AA in rats could reduce nuclide uptake of heart and declined myocardial ΔΨ_m.

Along with the extension of immunity time, mitochondrial ultrastructural damage occurred in the M₂AChR-el2-immunized group rats at 12th month after initial immunization. From electron micrographs, myocardial specimens from the M₂-AA group showed irregular distribution of mitochondria, varying degrees of mitochondrial swelling, cristae disappearance, and vacuolar degeneration (Fig 3B); moreover, the pathologic changes became more apparent at the 18th month of immunization. Deposition of dense granules in sarcoplasm and focal-dissolved myofibrils were also observed at the end of the experiment (Fig 3C). On the other hand,




Fig 3. Changes of myocardial $\Delta\Psi_m$ and mitochondrial ultrastructure during the active immunization process in rats. (A) Myocardial ^{99m}Tc -MIBI uptake ratio of H/M in two groups of rats after 12 months of immunization. The H/M in M₂-AA group rats decreased obviously compared to vehicle group rats. * $P < 0.05$, vs. vehicle group. H/M, ^{99m}Tc -MIBI uptake ratio of regions of interest positioned over the heart to mediastinum. Data are presented as mean \pm SEM. $n = 6/\text{group}$. Alterations in the myocardial mitochondrial ultrastructure in two groups of rats after 12 months (B) and 18 months (C) of immunization, respectively. Representative photomicrographs of the mid-papillary section of the heart from the vehicle group (panels B-I, C-II) and the M₂ group (panels B-II-III, C-II-IV) were shown. Panels B-I-III, C-II, C-III were photographed at $\times 10,000$ magnification and panels C-I and C-III were photographed at $\times 20,000$ magnification. The micrographs in M₂-AA group displayed the irregular distribution of mitochondria, swollen mitochondria, vacuolar degeneration (as the red arrow directed), focal dissolved myofibrils (as the blue arrow directed), and deposition of dense granules in the sarcoplasm (as the black arrow directed).

doi:10.1371/journal.pone.0129563.g003

the myocardial specimens from the vehicle group showed no obvious changes in mitochondrial ultrastructure.

The influence of long-term stimulation of M₂-AA on myocardial M₂ receptor binding characteristics in rats

To study the influence of myocardial M₂ receptor binding characteristics after long-term active immunization with M₂AChR-el2 antigen peptide in rats, the largest combination capacity (B_{max}) and dissociation constant (K_d) of M₂ muscarinic receptor were determined by RBA at the 12th and the 18th month post initial immunization. As shown in Table 2, in the M₂-AA group, the B_{max} value reduced significantly at the 18th month post M₂AChR-el2-immunization compared to the vehicle group, and the K_d value was up-regulated at the 18th month time-point compared to the vehicle group. These results indicated that the number of receptor sites

Table 2. [³H]-QNB saturation binding parameters from rat heart homogenates at 12 and 18 months post-immunization.

Saturation bindings	B _{max} (fmol/mg protein)	K _d (nmol/L)
Vehicle group	73.8±10.1	3.90±0.42
M ₂ -AA group (12th month)	82.8±9.8	5.37±0.38
M ₂ -AA group (18th month)	49.2±5.7*	8.50±0.22*

Data are presented as mean ± SEM (n = 6). [³H]-QNB: [³H]-quinuclidinyl benzylate.

*P<0.05 vs. Vehicle group.

doi:10.1371/journal.pone.0129563.t002

were down-regulated by prolonged exposure to M₂-AA; moreover, the remaining receptors were functionally declined.

Discussion

Dilated cardiomyopathy (DCM) is a cardiac disease characterized by ventricular cavity expansion and decline in contraction function. At present, etiology researches for DCM mainly focus on viral infection, cellular immunity, and autoimmunity; among which autoimmune mechanisms have received growing attention over the years [18]. The impact of autoimmune factors on heart disease has mainly focused on autoantibodies such as β₁-AA and M₂-AA [1]. In 1993, Fu *et al.* found that there was certain kind of autoantibody against M₂AChR-ε2 (M₂-AA) in DCM patients, which suggested that autoimmune factors may participate in the development of DCM [2]. In our current study, a M₂-AA positive rat model was established by method of active immunization with M₂AChR-ε2 and we found that: (1) long-term stimulation of M₂-AA resulted in reduced myocardial contractility and diastolic function at the 12th month, and both the systolic and diastolic dysfunction occurred at the 18th month time-point; meanwhile, M₂AChR-ε2-immunized rats developed DCM-like pathological features, such as ventricular cavity expansion and wall thinning; (2) decreased mitochondrial membrane potential and mitochondrial ultrastructural damage were detected in M₂-AA positive rats; and (3) the largest combination capacity (B_{max}) and affinity (1/K_d) of M₂ receptors decreased in myocardial tissue of active immunization rat. In summary, this study indicates that the elevated M₂-AA in the body could lead to myocardial mitochondrial damage, which may be one of potential causes for the decline in cardiac function and the compensatory expansion of ventricle which is similar to clinical features of DCM. Furthermore, down-regulation of M₂ receptor density and affinity induced by M₂-AA may also be involved in the process.

It has been shown that M₂-AA, a subtype of IgG2a autoantibody [19], can bind to M₂ receptors on cell surface and play a role similar to receptor agonist [2]. Wallukat G *et al.* observed a negative chronotropic effect of M₂-AA on myocytes *via* M₂ muscarinic receptor [20]. However, the pathophysiological roles of M₂-AA in the development of DCM need further exploration. In the present model, long-term presence of M₂-AA can lead to DCM-like morphological changes especially the right ventricular dilation, which is consistent with previous reports [5]. In addition, M₂-AA can gradually deteriorate cardiac systolic and diastolic function. Cardiac catheterization is a classical method for detecting cardiac hemodynamics. The dp/dt refers to first-order differential of ventricular systolic pressure, which will generate the curve of pressure variation rate. The maximum of dp/dt (+dp/dt_{max}) appeared in the first half of the isovolumic contraction period when preload and afterload are almost constant. Therefore, +dp/dt_{max} can be used as an important indicator to evaluate myocardial contractility under different functional statuses. Our study found that +dp/dt_{max} significantly declined at the 12th month after initial

immunization, which means that M₂-AA depleted the myocardial contraction force. However, LVSP which reflects the peak ventricular systolic pressure was still within normal range due to compensatory mechanisms. Until the end of the immunization, LVSP in M₂-AA group was significantly decreased, indicating ventricular systolic dysfunction (Fig 2A).

Ventricular diastole can be divided into two phases: active relaxation and passive stiffness. Ventricular active relaxation, mainly occurring in isovolumetric diastolic and rapid filling phases, needs to consume energy and can be represented by the change in diastolic pressure in the heart chamber per unit time (dp/dt). Ventricular passive stiffness mainly includes slow filling and atrial systolic phases during which no energy is needed. Either poor active relaxation or passive stiffness can induce elevated left ventricular end diastolic pressure (LVEDP). Additionally, LVEDP can be influenced by other factors, such as cardiac systolic force, heart rate, and intra-pericardial pressure, etc. Our study found that LVEDP increased at the 12th month, and was further elevated at the 18th month after initial immunization with M₂AChR-el2 (Fig 2B), indicating the gradual deterioration of cardiac diastolic function. The reasons for the diastolic dysfunction are complex, and may include a longer filling time, weaken myocardial contractility, delayed cross-bridge detachment and Ca²⁺ dissociation from troponin C caused by energy shortage (evidenced by decreased—dp/d_{max} in Fig 2D), myocardial remodeling, and limited myocardial compliance.

It is well known that there are abundant myofibrils and mitochondria in myocardial cells. Mitochondrial damage can lead to abnormal energy metabolism and cardiomyocyte deaths, both of which can lead to weakened cardiac contractility and relaxation. In this study, to detect whether mitochondria was involved in cardiac disorder caused by M₂-AA, myocardial mitochondrial membrane potential ($\Delta\Psi_m$) and ultrastructure changes were detected *via* radionuclide imaging and electron microscopy, respectively. Because of noninvasive examination, ^{99m}Tc-MIBI perfusion imaging is widely used in clinical applications to diagnose and assess various cardiac diseases. As a free cationic complex, approximately 90% of ^{99m}Tc-MIBI activity is associated with mitochondria in an energy-dependent manner *in vivo*. Previously, it has been shown that when mitochondrial membrane undergoes depolarization, uptake and retention of ^{99m}Tc-MIBI by myocardium is inhibited. Hence the mitochondrial membrane condition can be reflected by the uptake rate of ^{99m}Tc-MIBI [21]. Herein, we found that the $\Delta\Psi_m$ evidenced by ^{99m}Tc-MIBI uptake decreased in M₂-AA-positive rats at 12 months post initial immunization, which is indicative of impaired mitochondrial function [17]. Moreover, electron micrographs showed that myocardial mitochondria displayed irregular distribution, swelling, and vacuolation. These pathological mitochondrial perturbations became more severe at the end of the process of immunization. Numerous studies have demonstrated that swollen mitochondrion [22], vacuolar degeneration [23], and altered myocardial $\Delta\Psi_m$ [24] are widely used morphological and functional markers of abnormal mitochondria. These changes in mitochondria may lead to increased ROS formation, inhibition of mitochondrial respiratory chain, and eventually, cell death. While it is possible that attenuated cardiac systolic/diastolic function is due to abnormal energy metabolism from aberrant cellular activity as a result of mitochondrial damage, the exact mechanisms of M₂-AA-induced mitochondrial damage remain to be studied. Given that cardiomyocytes entirely depend on aerobic oxidation for energy supply, identification of contributory factors that cause mitochondrial damage will undoubtedly be of great significance for myocardial salvage.

Previously, we showed that an autoantibody against the second extracellular loop of β_1 -adrenoceptor (β_1 -AA), contributed to the development of DCM [25]. Although both β_1 -AA and M₂-AA have been shown to be involved in the development of DCM, they can lead to significantly different lesion characteristics. For example, (1) β_1 -AA-positive rat models established by active immunization exhibited elevated cardiac systolic and diastolic function at the

12th month, which decreased significantly at the 18th month after the initial immunization. On the other hand, cardiac dysfunction caused by M₂-AA became more and more serious with the extension of immunization time. (2) Long-term existence of β_1 -AA caused mitochondrial condensation, while vacuolar degeneration represented the main feature of M₂-AA-induced mitochondrial aberration. The data presented in the current study therefore suggests that M₂-AA may trigger unique mechanism in cardiac injury. Moreover, there may be crosstalk between M₂-AA and β_1 -AA, which could provide synergistic effects in causing declined cardiac function in DCM patients. It is also possible that the pathogenic role of M₂-AA is prior to that of β_1 -AA. Notably, Stavrakis *et al.* recently demonstrated that M₂-AA could neutralize the contractive effect of β_1 -AA on isolated Purkinje fibers [26], which further complicates the relationship between M₂-AA and β_1 -AA. Therefore, the detailed interplay of β_1 -AA and M₂-AA in DCM is worthy of further investigation.

M muscarinic receptors are cholinergic receptors that are widely present in humans. They are divided into three types, namely M₁, M₂, M₃ muscarinic receptor depending on their different expression sites and function. Among them, M₂ muscarinic receptor is mainly distributed in the heart and negatively regulates heart rate and contractile forces of cardiomyocytes, which balances with the roles of the β -adrenoceptor. In this study, specific ligands were bound directly to frozen heart tissue embedded on slides in order to measure maximal binding sites and affinity of specific receptors on cardiomyocytes in a manner that closely mimics *in vivo* condition. At the end of immunization, we found that M₂ receptor maximum binding capacity (B_{max}) decreased in M₂-AA active immunization model of DCM, suggesting a decrease in the expression of M₂ receptors; meanwhile, the dissociation constant (K_d) standing for M₂ receptor-ligand binding affinity was increased, implying a declined function of the available receptors. Receptor endocytosis is a significant mechanism of receptor degradation which can lead to decreased density of membrane receptor [27]. Delaney K.A, *et al.* reported that upon agonist stimulation, M₂ receptor was internalized *via* clathrin-independent pathway and resulted in decreased receptor density [28]. In our study, long term stimulation of M₂ receptor by M₂-AA may be the cause of decreased M₂ receptor density. The down-regulated affinity may be due to the changes of receptor conformation [29]. However, whether receptor endocytosis and conformational changes are critical mechanisms underlying reduced receptor binding ability need to be examined further. Additionally, associated signal pathways remain to be explored. However, studies have found that the inactivation of M muscarinic receptor plays an important role in cell apoptosis induced by mitochondrial injury or dysfunction [9]. This implies that decreased M₂ receptor binding ability may be involved in mitochondrial damage, which could further contribute to cardiomyocyte damage. Specifically, future studies need to examine whether M₂-AA can directly induce mitochondrial injury through interfering with M₂ receptor.

Unexpectedly, a disturbance in the ratio of CD4⁺ and CD8⁺ T cells was also observed during the process of M₂-AA-induced DCM in rats (S1 Fig). CD4⁺ and CD8⁺ are two subtypes of T lymphocytes which usually maintain a stable ratio under normal conditions, and often, increases or decreases in this ratio is indicative of autoimmune disorders. In this study, the CD4⁺/CD8⁺ ratio increased during the three months post-immunization, and decreased gradually after that. The increased CD4⁺/CD8⁺ ratio implied autoimmune hyperactivity during which more autoantibodies could be produced. This speculation was verified by the direct effect of M₂-AA on the proliferation of T lymphocytes *in vitro* (S2 Fig). However, the decreased CD4⁺/CD8⁺ ratio indicated the immune suppression. Taken together, long-term stimulation of M₂-AA can result in more severe immune imbalance; a likely vicious circle which should be further explored in the future studies.

Study limitations

In this study, we have observed that long-term exposure to M₂-AA results in DCM-like cardiac structural and functional changes, mitochondrial damage, and decreased M₂-AA receptor density and affinity; however, more *in vivo* and *in vitro* experiments are needed in our further studies to understand the causal relationship between them and the potential mechanisms.

Supporting Information

S1 Fig. Ratios of CD4⁺/CD8⁺ T lymphocyte subsets pre- and post-immunization with M₂AChR-el2 antigen peptides.

(PDF)

S2 Fig. The effect of M₂-AA on proliferation of cultured rat T lymphocyte *in vitro*.

(PDF)

Acknowledgments

The authors are grateful to Lindsey Devillier for providing editorial assistance with this manuscript.

Author Contributions

Conceived and designed the experiments: HL. Performed the experiments: SZ ZH Jin Wang LW YW TL. Analyzed the data: Jin Wang Jie Wang. Wrote the paper: SZ ZH Jin Wang LW YW TL HL.

References

1. Baba A, Yoshikawa T, Fukuda Y, Sugiyama T, Shimada M, Akaishi M, et al. Autoantibodies against M2-muscarinic acetylcholine receptors: new upstream targets in atrial fibrillation in patients with dilated cardiomyopathy. *Eur Heart J*. 2004; 25: 1108–1115. PMID: [15231368](#)
2. Fu LX, Magnusson Y, Bergh CH, Liljeqvist JA, Waagstein F, Hjalmarson A, et al. Localization of a functional autoimmune epitope on the muscarinic acetylcholine receptor-2 in patients with idiopathic dilated cardiomyopathy. *J Clin Invest*. 1993; 91: 1964–1968. PMID: [7683693](#)
3. Liu HR, Zhao RR, Zhi JM, Wu BW, Fu ML. Screening of serum autoantibodies to cardiac beta1-adrenoceptors and M2-muscarinic acetylcholine receptors in 408 healthy subjects of varying ages. *Autoimmunity*. 1999; 29: 43–51. PMID: [10052684](#)
4. Fu ML, Schulze W, Wallukat G, Hjalmarson A, Hoebeke J. Functional epitope analysis of the second extracellular loop of the human heart muscarinic acetylcholine receptor. *J Mol Cell Cardiol*. 1995; 27: 427–436. PMID: [7539085](#)
5. Yoshizawa A, Nagai S, Baba Y, Yamada T, Matsui M, Tanaka H, et al. Autoimmunity against M(2)muscarinic acetylcholine receptor induces myocarditis and leads to a dilated cardiomyopathy-like phenotype. *Eur J Immunol*. 2012; 42: 1152–1163. doi: [10.1002/eji.201142104](#) PMID: [22328321](#)
6. Zhang M, Wei J, Shan H, Wang H, Zhu Y, Xue J, et al. Calreticulin-STAT3 signaling pathway modulates mitochondrial function in a rat model of furazolidone-induced dilated cardiomyopathy. *PLoS One*. 2013; 8: e66779. doi: [10.1371/journal.pone.0066779](#) PMID: [23818963](#)
7. Cardena MM, Mansur AJ, Pereira AC, Fridman C. A new duplication in the mitochondrially encoded tRNA proline gene in a patient with dilated cardiomyopathy. *Mitochondrial DNA*. 2013; 24: 46–49. doi: [10.3109/19401736.2012.717933](#) PMID: [22954281](#)
8. De Sarno P, Shestopal SA, King TD, Zmijewska A, Song L, Jope RS. Muscarinic receptor activation protects cells from apoptotic effects of DNA damage, oxidative stress, and mitochondrial inhibition. *J Biol Chem*. 2003; 278: 11086–11093. PMID: [12538580](#)
9. Stope MB, Kunkel C, Kories C, Schmidt M, Michel MC. Differential agonist-induced regulation of human M2 and M3 muscarinic receptors. *Biochem Pharmacol*. 2003; 66: 2099–2105. PMID: [14609734](#)

10. Myslivecek J, Tillinger A, Novakova M, Kvetnansky R. Regulation of adrenoceptor and muscarinic receptor gene expression after single and repeated stress. *Ann N Y Acad Sci.* 2008; 1148: 367–376. doi: [10.1196/annals.1410.028](https://doi.org/10.1196/annals.1410.028) PMID: [19120130](https://pubmed.ncbi.nlm.nih.gov/19120130/)
11. Liu HR, Zhao RR, Jiao XY, Wang YY, Fu M. Relationship of myocardial remodeling to the genesis of serum autoantibodies to cardiac beta(1)-adrenoceptors and muscarinic type 2 acetylcholine receptors in rats. *J Am Coll Cardiol.* 2002; 39: 1866–1873. PMID: [12039504](https://pubmed.ncbi.nlm.nih.gov/12039504/)
12. Yan L, Xu Y, Yao H, Xue W, Tian J, Ren H, et al. The effects of autoantibodies against the second extracellular loop of alpha(1)-adrenoceptor on vasoconstriction. *Basic Res Cardiol.* 2009; 104: 581–589. doi: [10.1007/s00395-009-0020-8](https://doi.org/10.1007/s00395-009-0020-8) PMID: [19330480](https://pubmed.ncbi.nlm.nih.gov/19330480/)
13. Piwnica-Worms D, Kronauge JF, Chiu ML. Uptake and retention of hexakis (2-methoxyisobutyl isonitrite) technetium(I) in cultured chick myocardial cells. Mitochondrial and plasma membrane potential dependence. *Circulation.* 1990; 82: 1826–1838. PMID: [2225379](https://pubmed.ncbi.nlm.nih.gov/2225379/)
14. Wang L, Lu K, Hao H, Li X, Wang J, Wang K, et al. Decreased autophagy in rat heart induced by anti-beta1-adrenergic receptor autoantibodies contributes to the decline in mitochondrial membrane potential. *PLoS One.* 2013; 8: e81296. doi: [10.1371/journal.pone.0081296](https://doi.org/10.1371/journal.pone.0081296) PMID: [24278413](https://pubmed.ncbi.nlm.nih.gov/24278413/)
15. Vandermolen DT, Muntz KH, Buja LM. Quantification of beta-adrenergic receptors in canine cardiac myocytes using autoradiography and an internal standard. *Lab Invest.* 1986; 54: 353–359. PMID: [3005768](https://pubmed.ncbi.nlm.nih.gov/3005768/)
16. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. *Analy Biochem.* 1976; 72: 248. PMID: [942051](https://pubmed.ncbi.nlm.nih.gov/942051/)
17. Perry SW, Norman JP, Barbieri J, Brown EB, Gelbard HA. Mitochondrial membrane potential probes and the proton gradient: a practical usage guide. *BioTechniques.* 2011; 50: 98–115. doi: [10.2144/000113610](https://doi.org/10.2144/000113610) PMID: [21486251](https://pubmed.ncbi.nlm.nih.gov/21486251/)
18. Kawai C. From myocarditis to cardiomyopathy: mechanisms of inflammation and cell death: learning from the past for the future. *Circulation.* 1999; 99: 1091–1100. PMID: [10051305](https://pubmed.ncbi.nlm.nih.gov/10051305/)
19. Xiurui Ma, Jin Wang, Zi Yan, Yongqiang Guo, Ronghui Han, Sufen Li, et al. Distribution of the IgG subclass of autoantibodies against β_1/β_3 adrenoceptor or M2-muscarinic receptor in the sera of immunized rats. *Chinese Journal of Cardiovascular Research.* 2010; 8: 218–221.
20. Wallukat G, Fu M L, Magnusson Y, Hjalmarson A, Hoebcke J, Wollenberger A. Agonistic effects of anti-peptide antibodies and autoantibodies directed against adrenergic and cholinergic receptors: absence of desensitization. *Blood Press Suppl.* 1996; 3: 31–36. PMID: [8973766](https://pubmed.ncbi.nlm.nih.gov/8973766/)
21. Matsuo S, Nakae I, Tsutamoto T, Okamoto N, Horie M. A novel clinical indicator using Tc-99m sestamibi for evaluating cardiac mitochondrial function in patients with cardiomyopathies. *J Nucl Cardiol.* 2007; 14: 215–220. PMID: [17386384](https://pubmed.ncbi.nlm.nih.gov/17386384/)
22. Yan MX, Li YQ, Meng M, Ren HB, Kou Y. Long-term high-fat diet induces pancreatic injuries via pancreatic microcirculatory disturbances and oxidative stress in rats with hyperlipidemia. *Biochem Biophys Res Commun.* 2006; 347: 192–199. PMID: [16814251](https://pubmed.ncbi.nlm.nih.gov/16814251/)
23. Xu J, Hu ZQ, Wang C, Yin ZQ, Wei Q, Zhou LJ, et al. Acute and subacute toxicity study of 1,8-cineole in mice. *Int J Clin Exp Pathol.* 2014; 7: 1495–1501. PMID: [24817945](https://pubmed.ncbi.nlm.nih.gov/24817945/)
24. Kikusato M, Toyomizu M. Crucial role of membrane potential in heat stress-induced overproduction of reactive oxygen species in avian skeletal muscle mitochondria. *PLoS One.* 2013; 8: e64412. doi: [10.1371/journal.pone.0064412](https://doi.org/10.1371/journal.pone.0064412) PMID: [23671714](https://pubmed.ncbi.nlm.nih.gov/23671714/)
25. Zuo L, Bao H, Tian J, Wang X, Zhang S, He Z, et al. Long-term active immunization with a synthetic peptide corresponding to the second extracellular loop of beta1-adrenoceptor induces both morphological and functional cardiomyopathic changes in rats. *Int J Cardiol.* 2011; 149: 89–94. doi: [10.1016/j.ijcard.2009.12.023](https://doi.org/10.1016/j.ijcard.2009.12.023) PMID: [20096470](https://pubmed.ncbi.nlm.nih.gov/20096470/)
26. Stavrakis S, Kem D C, Patterson E, Lozano P, Huang S, Szabo B, et al. Opposing cardiac effects of autoantibody activation of beta-adrenergic and M2 muscarinic receptors in cardiac-related diseases. *Int J Cardiol.* 2011; 148: 331–336. doi: [10.1016/j.ijcard.2009.11.025](https://doi.org/10.1016/j.ijcard.2009.11.025) PMID: [20053466](https://pubmed.ncbi.nlm.nih.gov/20053466/)
27. Haglund K, Dikic I. The role of ubiquitylation in receptor endocytosis and endosomal sorting. *J Cell Sci.* 2012; 125: 265–275. doi: [10.1242/jcs.091280](https://doi.org/10.1242/jcs.091280) PMID: [22357968](https://pubmed.ncbi.nlm.nih.gov/22357968/)
28. Delaney KA, Murph MM, Brown LM, Radhakrishna H. Transfer of M₂ muscarinic acetylcholine receptors to clathrin-derived early endosomes following clathrin-independent endocytosis. *J Biol Chem.* 2002; 277: 33439–33446. PMID: [12093817](https://pubmed.ncbi.nlm.nih.gov/12093817/)
29. Bornholz B, Weidtkamp-Peters S, Schmitmeier S, Seidel CA, Herda LR, Felix SB, et al. Impact of human autoantibodies on β_1 -adrenergic receptor conformation, activity, and internalization. *Cardiovasc Res.* 2013; 97: 472–480. doi: [10.1093/cvr/cvs350](https://doi.org/10.1093/cvr/cvs350) PMID: [23208588](https://pubmed.ncbi.nlm.nih.gov/23208588/)